南方财经5月9日电，记者获悉，5月8日晚，科兴生物（Sinovac Biotech Ltd.）公布2025年上半年财报。财报显示，截至6月30日的六个月内，公司总销售额为1.303亿美元，较去年同期微增1.2%；但受资产减值及投资收益波动影响，归属于普通股股东的净亏损为2170万美元，而去年同期为净利润9390万美元。
业务层面，公司全球化战略成效显著，海外销售额同比增长29.4%，有效抵消了国内市场的需求放缓。期内，科兴连续中标智利流感疫苗全球招标，并与巴西卫生部签署十年期合作协议，将供应约6000万剂水痘和狂犬病疫苗，海外市场成为业绩核心支撑。
研发方面，上半年研发投入为1.27亿美元，占当期营收比重较高。管线进展上，破伤风疫苗已获批上市，狂犬病疫苗已提交上市申请；二价手足口病疫苗、13价肺炎球菌结合疫苗、全人源抗破伤风单抗均已进入III期临床。（21世纪经济报道）
（文章来源：南方财经网）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.